Share

Access to Health Care Press Releases

November 15, 2023

Mississippi Must Expand Medicaid and Stand Up to Big Tobacco

For cancer patients and survivors caught in the coverage gap, we know access to health care means comprehensive coverage for cessation and other resources to help Mississippians with limited incomes successfully quit smoking, but it also means access to screening, medications, and life-saving treatment.

October 27, 2023

In a New Brief, a Coalition of the Nation’s Leading Public Health Advocacy Organizations Urge the Court to Reject Efforts to Gut Access to Health Care for Immigrants

A coalition of the country’s leading public health advocacy organizations filed a friend-of-the-court brief in Texas v. Mayorkas in the United States District Court for the Southern District of Texas to urge the court to uphold the Biden administration’s 2022 “public charge” policy. Amici include American Cancer Society; American Cancer Society Cancer Action Network (ACS CAN); American Lung Association; CancerCare; Epilepsy Foundation; Hemophilia Federation of America; Leukemia & Lymphoma Society; Muscular Dystrophy Association; National Multiple Sclerosis Society; National Patient Advocate Foundation; and Susan G. Komen. 

October 12, 2023

After Over 15 Years, Legislature Passes Oral Chemotherapy Legislation

Today, the American Cancer Society Cancer Action Network (ACS CAN) was overjoyed to see the legislature pass oral chemotherapy fairness legislation. ACS CAN looks forward to seeing the Governor sign this critical legislation into law soon and celebrating our volunteers’ hard work to get this legislation over the finish line.

October 4, 2023

CMS Should Prioritize Patients’ Experience as the Administration Negotiates Drug Prices for 2026 Plans

Earlier this week, 22 cancer patient and caregiver advocacy groups, including the American Cancer Society Cancer Action Network (ACS CAN), sent a letter to the Centers for Medicare & Medicaid Services (CMS) offering recommendations on how the agency should consider pharmaceutical therapeutic alternatives to selected oncology drugs for 2026 Medicare plans as they head into the negotiation process laid out in the Inflation Reduction Act (IRA).